Table 1 Clinical characteristics
From: Eukaryotic Initiation Factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer
Variable | No. of patients (%) |
|---|---|
Total | 122 (100%) |
Age (median, 56 years) | Â |
   <56 years | 68 (55.7%) |
   ≥56 years | 54 (44.3%) |
Surgical treatment | Â |
   Breast conservation | 29 (23.8%) |
   Mastectomy | 93 (76.2%) |
Tumor size (mean, 3.1 cm) | Â |
   <3.1 cm | 70 (57.4%) |
   ≥3.1 cm | 52 (42.6%) |
Histological diagnosis | Â |
   Invasive carcinoma | 102 (83.6%) |
Ductal | 80 (65.6%) |
Lobular | 14 (11.5%) |
Medullary | 6 (4.9%) |
Tubular | 2 (1.6%) |
   Non invasive carcinoma | 20 (16.4%) |
DCIS | 15 (12.3%) |
LCIS | 5 (4.1%) |
Histological grade | Â |
   Invasive carcinoma | 102 (83.6%) |
Grade I | 27 (22.1%) |
Grade II | 41 (33.6%) |
Grade III | 34 (27.9%) |
   Non invasive carcinoma | 20 (16.4%) |
Low grade | 5 (4.1%) |
Intermediate grade | 3 (2.5%) |
High grade | 12 (9.8%) |
TNM staging | Â |
   Stage I | 30 (24.6%) |
   Stage II | 33 (27.1%) |
   Stage III | 37 (30.3%) |
   Stage IV | 22 (18.0%) |
Node metastatic status | Â |
   Negative | 48 (39.3%) |
   Positive | 74 (60.7%) |
Estrogen Receptor status | Â |
   Negative | 54 (44.3%) |
   Positive | 68 (55.7%) |
Progesterone Receptor status | Â |
   Negative | 65 (53.3%) |
   Positive | 57 (46.7%) |
Her-2/neu status | Â |
   Negative | 66 (54.1%) |
   Positive | 56 (45.9%) |
Clinical outcome | Â |
   Disease free | 77 (63.1%) |
   Metastasis or recurrence | 45 (36.9%) |
   Died for breast cancer | 30 (24.6%) |